These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26449448)

  • 1. The role of clinically-relevant parameters on the cohesiveness of sclerosing foams in a biomimetic vein model.
    Carugo D; Ankrett DN; O'Byrne V; Wright DD; Lewis AL; Hill M; Zhang X
    J Mater Sci Mater Med; 2015 Nov; 26(11):258. PubMed ID: 26449448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of polidocanol endovenous microfoam (Varithena®) compared with physician-compounded foams.
    Carugo D; Ankrett DN; Zhao X; Zhang X; Hill M; O'Byrne V; Hoad J; Arif M; Wright DD; Lewis AL
    Phlebology; 2016 May; 31(4):283-95. PubMed ID: 26036246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel developments in foam sclerotherapy: Focus on Varithena® (polidocanol endovenous microfoam) in the management of varicose veins.
    Star P; Connor DE; Parsi K
    Phlebology; 2018 Apr; 33(3):150-162. PubMed ID: 28166694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and ex vivo evaluation of the biological performance of sclerosing foams.
    Bottaro E; Paterson JAJ; Quercia L; Zhang X; Hill M; Patel VA; Jones SA; Lewis AL; Millar TM; Carugo D
    Sci Rep; 2019 Jul; 9(1):9880. PubMed ID: 31285447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical Vein Models to Quantify the Flow Performance of Sclerosing Foams.
    Bottaro E; Paterson J; Zhang X; Hill M; Patel VA; Jones SA; Lewis AL; Millar TM; Carugo D
    Front Bioeng Biotechnol; 2019; 7():109. PubMed ID: 31165068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foam-in-Vein: Characterisation of Blood Displacement Efficacy of Liquid Sclerosing Foams.
    Meghdadi A; Jones SA; Patel VA; Lewis AL; Millar TM; Carugo D
    Biomolecules; 2022 Nov; 12(12):. PubMed ID: 36551153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel biomimetic analysis system for quantitative characterisation of sclerosing foams used for the treatment of varicose veins.
    Carugo D; Ankrett DN; O'Byrne V; Willis S; Wright DD; Lewis AL; Hill M; Zhang X
    J Mater Sci Mater Med; 2013 Jun; 24(6):1417-23. PubMed ID: 23512153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Truncal Incompetence and Varicose Veins with a Single Administration of a New Polidocanol Endovenous Microfoam Preparation Improves Symptoms and Appearance.
    King JT; O'Byrne M; Vasquez M; Wright D;
    Eur J Vasc Endovasc Surg; 2015 Dec; 50(6):784-93. PubMed ID: 26384639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation and optimisation of foams for varicose vein sclerotherapy.
    Roberts TG; Cox SJ; Lewis AL; Jones SA
    Biorheology; 2020; 57(2-4):77-85. PubMed ID: 33459690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Size of Sclerosing Foams Prepared by Ultrasound, Mechanical Agitation, and the Handmade Tessari Method for Treatment of Varicose Veins.
    Critello CD; Fiorillo AS; Matula TJ
    J Ultrasound Med; 2017 Mar; 36(3):649-658. PubMed ID: 28127790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of cerebrovascular gas emboli during polidocanol endovenous ultra-low nitrogen microfoam ablation and correlation with magnetic resonance imaging in patients with right-to-left shunt.
    Regan JD; Gibson KD; Rush JE; Shortell CK; Hirsch SA; Wright DD
    J Vasc Surg; 2011 Jan; 53(1):131-7. PubMed ID: 20864303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties of polidocanol foam in view of its use in sclerotherapy.
    Nastasa V; Samaras K; Ampatzidis Ch; Karapantsios TD; Trelles MA; Moreno-Moraga J; Smarandache A; Pascu ML
    Int J Pharm; 2015 Jan; 478(2):588-96. PubMed ID: 25433198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence.
    Todd KL; Wright DI;
    Phlebology; 2014 Oct; 29(9):608-18. PubMed ID: 23864535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Stability of Physician-Compounded Foam is Influenced by the Angle of Connector.
    Shi X; Liu Y; Li D; Tursun M; Azmoun S; Liu S
    Ann Vasc Surg; 2024 Feb; 99():217-222. PubMed ID: 37852364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous disorders: treatment with sclerosant foam.
    Bergan J; Pascarella L; Mekenas L
    J Cardiovasc Surg (Torino); 2006 Feb; 47(1):9-18. PubMed ID: 16434941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerosant foam structure and stability is strongly influenced by liquid air fraction.
    Cameron E; Chen T; Connor DE; Behnia M; Parsi K
    Eur J Vasc Endovasc Surg; 2013 Oct; 46(4):488-94. PubMed ID: 23993276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerotherapy and foam sclerotherapy for varicose veins.
    Coleridge Smith P
    Phlebology; 2009 Dec; 24(6):260-9. PubMed ID: 19952382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new method for using radiopaque sclerosing foam to treat venous malformations.
    Li K; Liu YR; Chen AW; Liu SH
    Dermatol Surg; 2015 Jun; 41(6):726-30. PubMed ID: 25973562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerotherapy: a study comparing polidocanol in foam and liquid form.
    Uncu H
    Phlebology; 2010 Feb; 25(1):44-9. PubMed ID: 20118346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Foam and liquid sclerotherapy for varicose veins.
    Coleridge Smith P
    Phlebology; 2009; 24 Suppl 1():62-72. PubMed ID: 19307442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.